Siliq

Drug Overview

SILIQ (brodalumab) is a high-potency BIOLOGIC and a specialized IMMUNOMODULATOR within the IMMUNOLOGY drug category. As a first-in-class TARGETED THERAPY, it is a human MONOCLONAL ANTIBODY that functions as an INTERLEUKIN-17 (IL-17) RECEPTOR ANTAGONIST. While other biologics in this class bind to the inflammatory cytokines themselves, Siliq is unique because it targets the receptor “docking station” on the cell surface.

This medication is specifically engineered for patients with chronic, systemic inflammatory skin conditions who have not found success with traditional systemic treatments. By blocking the gateway for multiple inflammatory signals, Siliq provides a robust mechanism for achieving clear or almost clear skin.

• Generic Name: Brodalumab
• US Brand Name: Siliq
• Route of Administration: Subcutaneous (SC) Injection
• FDA Approval Status: FDA-approved for adults with moderate-to-severe plaque psoriasis.
  
  Find essential details regarding Siliq, a well-known IL-17 Receptor Antagonist optimized for treating Plaque Psoriasis (Brodalumab). Discover how our specialists integrate it into patient care plans.

What Is It and How Does It Work? (Mechanism of Action)

Siliq functions through SELECTIVE RECEPTOR BLOCKADE. Its primary target is the Interleukin-17 Receptor A (IL-17RA). To understand its potency, it is helpful to look at the “IL-23/IL-17 axis,” which is the central driver of psoriasis.

Molecular and Cellular Level Action

In a person with psoriasis, immune cells overproduce several types of IL-17 cytokines (such as IL-17A, IL-17F, and IL-17A/F). These cytokines act like “keys” that travel to skin cells (keratinocytes) and unlock the inflammatory process, leading to the rapid overproduction of skin cells and the formation of thick, red, scaly plaques.

1. Direct Receptor Binding: Siliq binds with high affinity to the IL-17RA subunit.
2. Comprehensive Blockade: Unlike other BIOLOGICS that only “catch” one type of cytokine (like IL-17A), Siliq blocks the receptor itself. This effectively prevents multiple members of the IL-17 family—including IL-17A, IL-17F, and IL-17C—from connecting with the cell.
3. Inhibition of Signaling: Once the receptor is blocked, the “pro-inflammatory cascade” is halted. The skin cells stop receiving signals to hyper-proliferate.
4. Resolution of Inflammation: This leads to a rapid decrease in the thickness, redness, and scaling of psoriasis plaques, as the underlying IMMUNOLOGY of the skin returns to a state of homeostasis.

FDA-Approved Clinical Indications

Primary Indication

The primary indication for Siliq is the treatment of moderate-to-severe PLAQUE PSORIASIS in adult patients who are candidates for systemic therapy or phototherapy and have failed to respond, or have lost response, to other systemic therapies.

Other Approved & Off-Label Uses

While plaque psoriasis is the primary focus in the U.S., the underlying mechanism of brodalumab has led to international use and research in other areas:

• Psoriatic Arthritis (PsA): Approved in certain international markets for joint involvement associated with psoriasis.
• Axial Spondyloarthritis: Actively researched for its role in reducing spinal inflammation.
• Generalized Pustular Psoriasis: Investigated for severe, rare “flare” forms of the disease.

Primary Immunology Indications

• Receptor Antagonism: Preventing the activation of the IL-17 signaling pathway at the cellular gateway.
• Cytokine Regulation: Indirectly lowering the systemic levels of secondary inflammatory markers like CRP.
• Prevention of Systemic Damage: Reducing chronic inflammation that can contribute to cardiovascular comorbidities.

Dosage and Administration Protocols

Siliq is administered via subcutaneous injection. Patients are typically trained to self-administer the medication at home using a pre-filled syringe.

Dose Adjustments and Specialized Protocols:

• Response Assessment: If a patient does not show a significant clinical response after 12 to 16 weeks of treatment, the physician may consider discontinuing the drug.
• Storage: The pre-filled syringes must be stored in the refrigerator. Before injection, the syringe should be allowed to reach room temperature (about 30 minutes) to reduce discomfort.
• Underlying Infections: Treatment should not be initiated in patients with clinically important active infections until the infection resolves.

Clinical Efficacy and Research Results

The efficacy of Siliq was established through the AMAGINE-1, AMAGINE-2, and AMAGINE-3 pivotal Phase 3 clinical trials (2015–2020), with ongoing real-world data continuing through 2026.

Numerical Research Data

• PASI 75/90/100 Scores: In the AMAGINE trials, Siliq demonstrated some of the highest skin clearance rates in the BIOLOGIC category. Approximately 83% of patients achieved PASI 75 (75% clearance), and nearly 44% achieved PASI 100 (total skin clearance) by week 12.
• Head-to-Head Comparison: In trials comparing Siliq to ustekinumab, Siliq showed superior PASI 100 rates at week 12 (44% vs. 22%).
• Speed of Action: Data through 2026 confirms that many patients see a 50% reduction in skin symptoms as early as week 2 or 4 of the induction phase.
• Durability: Among patients who achieved a response at week 12, over 70% maintained clear or almost clear skin through one year of continuous maintenance therapy.

Safety Profile and Side Effects

BLACK BOX WARNING

Siliq carries a Black Box Warning for Suicidal Ideation and Behavior. A small number of suicidal ideation and behaviors, including completed suicides, occurred in clinical trials. Siliq is only available through a restricted program called the SILIQ REMS (Risk Evaluation and Mitigation Strategy). Patients with a history of depression or suicidal thoughts must be evaluated carefully before starting treatment.

Common Side Effects (>10%)

• Arthralgia: Joint pain.
• Headache: Mild to moderate systemic response.
• Fatigue: General tiredness, common in the induction phase.
• Oropharyngeal Pain: Sore throat.

Serious Adverse Events

• Serious Infections: Increased risk of bacterial, viral, or fungal infections due to IMMUNOMODULATOR activity.
• Crohn’s Disease: Siliq can trigger or worsen inflammatory bowel disease. It is contraindicated in patients with Crohn’s disease.
• Neutropenia: A drop in infection-fighting white blood cells.

Research Areas

Direct Clinical Connections

Active research in 2025 and 2026 is exploring the drug’s interaction with the “Gut-Skin Axis.” Because IL-17 receptors are also found in the intestinal lining, researchers are investigating how receptor blockade differs from cytokine-specific blockade in patients who may have undiagnosed subclinical bowel inflammation.

Generalization

The field of TARGETED THERAPY is shifting toward “Interchangeability.” Research is ongoing regarding the safety of switching patients between different IL-17 inhibitors. Additionally, advancements in Novel Delivery Systems are being evaluated, specifically autoinjectors with thinner needles to improve patient compliance and comfort for home-based care.

Severe Disease & Multi-Organ Involvement

Recent studies (2024–2026) are tracking whether Siliq’s rapid clearance of skin inflammation can lower systemic vascular inflammation, potentially reducing the risk of “MACE” (Major Adverse Cardiovascular Events) in severe psoriasis patients.

Disclaimer: The research discussed regarding subcutaneous delivery formulations, potential applications in cytokine release syndrome (CRS), and long-term regulatory T-cell (Treg) expansion is currently in the investigational phase and is not yet applicable to standard professional clinical scenarios. 

Patient Management and Clinical Protocols

Pre-treatment Assessment

• Baseline Diagnostics: A QuantiFERON-TB Gold test is mandatory to rule out latent tuberculosis.
• Organ Function: Complete Blood Count (CBC) to check for baseline neutropenia.
• Specialized Testing: A thorough mental health screening and a history of inflammatory bowel disease (Crohn’s or UC) are essential.
• Screening: Review of vaccination history. Live vaccines should be administered at least 4 weeks before starting Siliq.

Monitoring and Precautions

• Vigilance: Patients and caregivers must monitor for new or worsening symptoms of depression, anxiety, or suicidal thoughts.
• REMS Compliance: Both the prescriber and the patient must be enrolled in the Siliq REMS program.
• Periodic Exams: Regular check-ins every 3 to 6 months to monitor for infections and mental health status.

Do’s and Don’ts for Immunocompromised Patients:

• DO report any fever, persistent cough, or localized pain immediately.
• DO inform your dermatologist if you have a change in bowel habits or abdominal pain.
• DO discuss any history of mood disorders with your medical team.
• DON’T receive “live” vaccines (like MMR or shingles) while on Siliq.
• DON’T stop the medication without a physician-guided plan, as this can cause a “rebound” flare.
• DON’T share your pre-filled syringes with others.

Legal Disclaimer

This guide is for informational purposes only and does not constitute medical advice, diagnosis, or treatment. Siliq (brodalumab) is a potent TARGETED THERAPY that must be prescribed and monitored by a qualified dermatologist or rheumatologist. Always seek the advice of your physician regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read in this guide. Due to the Black Box Warning, Siliq requires strict adherence to the REMS safety program.